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Aim: To point out the psychological particularities in children with cystic ﬁbrosis
(CF), family relationships and the elaboration of a methodological set of their
psychological support.
Materials and Methods: The examination of psychological particularities of the
given sick children, the test of family relationships and of their inﬂuence upon the
disease evolution, the elaboration and implementation of a methodological set for
psychological support of the sick children and family environment were performed.
In the frame of this research 19 children with diagnosis of CF have been interviewed
as well as their mothers. The conversation, observation, the analysis (MMPI, 16 PF –
Cattell, Leary, State Trait Anxiety Inventory, the projective test, PARI, the test of
family relationships, the sentences fulﬁllment, self-appreciation of social importance
of the disease, the family picture) methods were used in group of study.
Results: After processing of the results we obtained a high anxiety, aggressive
tendencies, inhibition, emotional rigidity, phobias, negative thinking in children; in
mothers – hyper-protection, the phobia of loosing the child, the sexuality inhibition,
mother dependence, and familial conﬂicts – divorces. All these serve as causes for
the elaboration of a methodological set of a psychological support. This set is
based on the supportive psychotherapy which includes especially some techniques
from the cognitive-behavioral therapy: strategies focused on the problem through
strategies of avoidance and active behavioral strategies.
Conclusion: the intervened changes in the life of children with CF are the limitation
of physical and psychical capacities in the normal activity, ambient and relational
changes, with major inﬂuence in the affective sphere.
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Background: With improvement of survival, an increasing number of CF patients,
become parents. During the pregnancy women with CF can be less intensive treated
due to anxiety of possible adverse effects on the foetus. After the birth, parents are
at increased risk of viral infections transmitted from the child. Furthermore the risk
of decreased adherence to the treatment after the child birth can be a problem. We
wanted to investigate a possible negative impact of these factors on lung function
and BMI in a population a CF patients who became parents.
Methods: All CF patients chronically infected with P.aeruginosa followed in the
Copenhagen CF centre, who had become parent during the last 10 years, were
included. Men and women were studied separately. Lung functions and nutritional
data were collected from visits in the clinic in the year prior to pregnancy and in the
ﬁrst 2 years after birth of the child. Results were compared using a paired Students
t-test.
Results: 13 patients were included (7 males). In the female group, FEV1 changed
from a median of 62.5% (range 36.1−91.4) in the year prior to pregnancy to 57.5%
(range 27.9−90.1) in the ﬁrst year after childbirth (p< 0.04) and to 58.1% (range
29.1−75.1) in the second year after childbirth (p< 0.02). In the male group, median
FEV1 was 73.7% predicted (range 35.1−95.4) in the year prior to pregnancy. In the
ﬁrst year of the child, FEV1 was 68.3% (range 32.9−88.3) (n.s.) and in the second
year, FEV1 changed to 66% (range 36.1−81.3) (p< 0.001). We found no change in
BMI in either group.
Conclusion: Becoming a parent can have a negative impact on progression of CF
lung diseases. The possible explanation can be less intensive antibiotic treatment,
increased risk of viral infections and reduced adherence to the treatment. Further
analysis on larger groups of patients is needed.
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Aims: Taking care of cystic ﬁbrosis (CF) patients might represent a condition of
distress, burden and concerns. The aim of the study was to: 1) translate the original
Caregiver Quality of Life Cystic Fibrosis (CQOLCF) Scale (Boling W. et al., 2003)
into Italian and 2) to psychometrically evaluate the Italian version of the CQOLCF
in the Italian population.
Methods: The linguistic validation of the CQOLCF followed the international
guidelines by Guillemin et al. and by the MAPI Research Institute, suggesting the
“forward-backward-forward” translation. Once the Italian CQOLCF was created,
15 CF caregivers were interviewed and asked to indicate the clarity of each item
and the risk to misunderstand the questions. The administration started on January
2008 and will include all those subjects (at least 200), identiﬁed as the CF family
caregivers (>18 years), attending the CF Unit with their loved one (with a conﬁrmed
diagnosis of CF). They will be asked to complete: informed consent, anagraphic
sheet, CQOLCF, Short-Form Health Survey 36 (SF-36), CES-D and State-Trait
Anxiety Inventory (STAI Y1-Y2). The physician will be asked to assess the clinical-
medical variables for each CF patient cared by the CF caregiver: FEV1, BMI,
pancreatic status, infections, on a waiting list for a transplant.
Results: the Italian CQOLCF resulted to have a good face validity and was
positively accepted by all the subjects recruited. Future analyses on the statistical
properties of the CQOLCF will explore internal consistency, concurrent validity,
test-retest validity and disciminatory ability.
Conclusions: once fully validated, the CQOLCF might be a valid tool in research
and clinical practice with CF caregivers.
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The Challenge of Living with Cystic Fibrosis (CLCF) questionnaire aims to assess
the impact of new interventions on caregivers in clinical trials. This PRO was
developed with CF professionals and parents with action research methods and is
designed to capture the experience of bringing up a child with CF from 1 year post
diagnosis to 13 years. We report the instrument’s validation with n = 300 caregivers
examining ﬂoor and ceiling effects and internal reliability. Concurrent validity
assesses the CLCF’s correlation with the Cystic Fibrosis Questionnaire (CFQ)
and clinical severity indexes (FEV1% predicted, Chest X-ray and Schwachman
Scores). Divergent validity tests the instrument’s ability to distinguish between:
(i) age groups, (ii) presence/absence of pseudomonal airways infection, and
(iii) genotypes. Caregivers of younger and older children differ in the way they
administer enzymes – caregivers of younger children spent more time [median
(95%CI) difference in minutes per day: 9.59 (2.20)]. This corresponded to the ease
with which caregivers thought they were managing this task and suggests an age-
speciﬁc proﬁle. Respondents report that completing the CLCF is useful to reﬂect
on their experience and to record how they are coping with this complex challenge.
It offers a framework for caregivers to raise any difﬁculties and has potential as a
clinical tool at annual review as well as a research tool in clinical trials.
